Kent Hutchison
Concepts (550)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 65 | 2023 | 817 | 9.890 |
Why?
| | Alcohol Drinking | 48 | 2024 | 826 | 6.700 |
Why?
| | Cues | 38 | 2018 | 326 | 4.890 |
Why?
| | Brain | 56 | 2026 | 2933 | 4.830 |
Why?
| | Cannabis | 22 | 2026 | 509 | 4.200 |
Why?
| | Cannabidiol | 12 | 2025 | 136 | 4.080 |
Why?
| | Dronabinol | 17 | 2025 | 247 | 3.970 |
Why?
| | Ethanol | 31 | 2021 | 627 | 3.630 |
Why?
| | Alcohol-Related Disorders | 17 | 2021 | 120 | 3.550 |
Why?
| | Magnetic Resonance Imaging | 61 | 2026 | 3863 | 3.010 |
Why?
| | Tobacco Use Disorder | 15 | 2021 | 218 | 2.900 |
Why?
| | Smoking | 30 | 2019 | 1472 | 2.690 |
Why?
| | Marijuana Abuse | 16 | 2024 | 211 | 2.680 |
Why?
| | Hallucinogens | 6 | 2026 | 108 | 2.650 |
Why?
| | Cannabinoids | 9 | 2026 | 182 | 2.580 |
Why?
| | Marijuana Use | 8 | 2025 | 213 | 2.440 |
Why?
| | Substance-Related Disorders | 19 | 2023 | 1094 | 2.290 |
Why?
| | Receptors, Dopamine D2 | 10 | 2018 | 93 | 2.150 |
Why?
| | Behavior, Addictive | 14 | 2021 | 88 | 2.100 |
Why?
| | Adult | 141 | 2026 | 40449 | 2.020 |
Why?
| | Gray Matter | 7 | 2023 | 91 | 1.970 |
Why?
| | Nerve Net | 10 | 2023 | 285 | 1.800 |
Why?
| | Brain Mapping | 14 | 2023 | 536 | 1.740 |
Why?
| | Reward | 11 | 2018 | 247 | 1.700 |
Why?
| | Polymorphism, Genetic | 14 | 2012 | 612 | 1.680 |
Why?
| | Varenicline | 4 | 2017 | 28 | 1.660 |
Why?
| | Neuroimaging | 10 | 2026 | 289 | 1.590 |
Why?
| | Marijuana Smoking | 7 | 2021 | 250 | 1.570 |
Why?
| | Receptors, Dopamine D4 | 11 | 2011 | 26 | 1.540 |
Why?
| | Young Adult | 62 | 2026 | 14105 | 1.520 |
Why?
| | Male | 152 | 2026 | 72315 | 1.510 |
Why?
| | Female | 154 | 2026 | 78271 | 1.450 |
Why?
| | Genotype | 24 | 2014 | 1833 | 1.440 |
Why?
| | Substance Withdrawal Syndrome | 13 | 2019 | 186 | 1.430 |
Why?
| | Naltrexone | 12 | 2019 | 117 | 1.410 |
Why?
| | Executive Function | 5 | 2020 | 461 | 1.400 |
Why?
| | Humans | 203 | 2026 | 144759 | 1.390 |
Why?
| | White Matter | 3 | 2021 | 153 | 1.350 |
Why?
| | Flowers | 4 | 2024 | 70 | 1.340 |
Why?
| | Mindfulness | 2 | 2023 | 155 | 1.270 |
Why?
| | Reflex, Startle | 9 | 2005 | 76 | 1.270 |
Why?
| | DNA Methylation | 9 | 2018 | 681 | 1.260 |
Why?
| | Alcoholic Intoxication | 5 | 2021 | 74 | 1.210 |
Why?
| | Middle Aged | 72 | 2026 | 35875 | 1.190 |
Why?
| | Central Nervous System Depressants | 10 | 2018 | 83 | 1.180 |
Why?
| | Gyrus Cinguli | 7 | 2017 | 96 | 1.110 |
Why?
| | Polymorphism, Single Nucleotide | 27 | 2018 | 2145 | 1.090 |
Why?
| | Cigarette Smoking | 3 | 2018 | 99 | 1.080 |
Why?
| | Narcotic Antagonists | 9 | 2019 | 205 | 1.060 |
Why?
| | Endocannabinoids | 2 | 2026 | 57 | 1.050 |
Why?
| | Affect | 14 | 2024 | 318 | 1.040 |
Why?
| | Receptors, Opioid, mu | 6 | 2018 | 68 | 1.030 |
Why?
| | Receptor, Cannabinoid, CB1 | 5 | 2012 | 39 | 1.010 |
Why?
| | Smoking Cessation | 10 | 2017 | 439 | 1.010 |
Why?
| | Taste | 5 | 2018 | 239 | 1.010 |
Why?
| | Receptors, Nicotinic | 5 | 2014 | 321 | 0.990 |
Why?
| | Alcoholic Beverages | 3 | 2017 | 31 | 0.990 |
Why?
| | Medical Marijuana | 4 | 2025 | 123 | 0.980 |
Why?
| | Motivation | 14 | 2015 | 610 | 0.980 |
Why?
| | Functional Neuroimaging | 9 | 2017 | 60 | 0.950 |
Why?
| | Impulsive Behavior | 9 | 2017 | 146 | 0.950 |
Why?
| | Psilocybin | 1 | 2026 | 4 | 0.950 |
Why?
| | Toll-Like Receptor 4 | 2 | 2018 | 276 | 0.940 |
Why?
| | Cognitive Neuroscience | 1 | 2025 | 9 | 0.910 |
Why?
| | Esthetics | 1 | 2025 | 41 | 0.900 |
Why?
| | Aging | 6 | 2026 | 1966 | 0.900 |
Why?
| | Eicosanoids | 1 | 2025 | 58 | 0.890 |
Why?
| | Amidohydrolases | 3 | 2009 | 32 | 0.880 |
Why?
| | Arousal | 6 | 2018 | 157 | 0.870 |
Why?
| | Nicotine | 12 | 2019 | 331 | 0.870 |
Why?
| | Nicotinic Agonists | 6 | 2017 | 136 | 0.870 |
Why?
| | Minisatellite Repeats | 9 | 2011 | 36 | 0.840 |
Why?
| | Taste Perception | 3 | 2015 | 31 | 0.810 |
Why?
| | DNA Copy Number Variations | 4 | 2012 | 183 | 0.800 |
Why?
| | Benzodiazepines | 6 | 2014 | 167 | 0.790 |
Why?
| | Phenotype | 12 | 2015 | 3162 | 0.750 |
Why?
| | Risk-Taking | 5 | 2021 | 328 | 0.740 |
Why?
| | Cerebral Cortex | 9 | 2022 | 464 | 0.730 |
Why?
| | Anti-Inflammatory Agents | 1 | 2025 | 474 | 0.690 |
Why?
| | Cognition | 4 | 2025 | 1266 | 0.690 |
Why?
| | Parietal Lobe | 4 | 2014 | 60 | 0.690 |
Why?
| | Irritable Bowel Syndrome | 2 | 2019 | 29 | 0.680 |
Why?
| | Public Health | 1 | 2026 | 566 | 0.650 |
Why?
| | Adolescent | 43 | 2025 | 22428 | 0.630 |
Why?
| | Sensation Disorders | 1 | 2020 | 41 | 0.630 |
Why?
| | Exercise | 8 | 2023 | 2201 | 0.620 |
Why?
| | Dopamine | 5 | 2013 | 283 | 0.620 |
Why?
| | Antipsychotic Agents | 3 | 2014 | 213 | 0.610 |
Why?
| | Psychotherapy, Brief | 2 | 2011 | 41 | 0.610 |
Why?
| | Food | 3 | 2017 | 149 | 0.610 |
Why?
| | Psychomotor Performance | 5 | 2013 | 328 | 0.600 |
Why?
| | Motor Activity | 3 | 2013 | 721 | 0.600 |
Why?
| | Genetic Variation | 5 | 2012 | 983 | 0.590 |
Why?
| | Genetic Predisposition to Disease | 6 | 2013 | 2363 | 0.580 |
Why?
| | Exons | 2 | 2011 | 358 | 0.570 |
Why?
| | Diffusion Tensor Imaging | 3 | 2015 | 73 | 0.570 |
Why?
| | Plant Extracts | 1 | 2020 | 187 | 0.570 |
Why?
| | Models, Biological | 3 | 2015 | 1821 | 0.570 |
Why?
| | Self Report | 6 | 2021 | 872 | 0.560 |
Why?
| | Stress, Psychological | 5 | 2012 | 1152 | 0.550 |
Why?
| | Double-Blind Method | 16 | 2024 | 2029 | 0.540 |
Why?
| | Severity of Illness Index | 8 | 2018 | 2925 | 0.530 |
Why?
| | Receptors, GABA-A | 2 | 2009 | 138 | 0.510 |
Why?
| | Drinking | 1 | 2017 | 42 | 0.510 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 208 | 0.510 |
Why?
| | Exploratory Behavior | 4 | 2009 | 86 | 0.510 |
Why?
| | Decision Making | 4 | 2018 | 975 | 0.500 |
Why?
| | Saliva | 3 | 2019 | 249 | 0.490 |
Why?
| | Craving | 5 | 2023 | 39 | 0.490 |
Why?
| | Oxygen | 7 | 2013 | 995 | 0.490 |
Why?
| | Nerve Fibers, Myelinated | 2 | 2013 | 47 | 0.480 |
Why?
| | Catechol O-Methyltransferase | 3 | 2011 | 20 | 0.480 |
Why?
| | Mental Disorders | 6 | 2025 | 1168 | 0.480 |
Why?
| | Sex Characteristics | 6 | 2021 | 790 | 0.470 |
Why?
| | Corpus Striatum | 4 | 2017 | 179 | 0.470 |
Why?
| | Heart Rate | 9 | 2018 | 855 | 0.450 |
Why?
| | Brain Injuries, Traumatic | 2 | 2021 | 441 | 0.450 |
Why?
| | Coronary Disease | 1 | 2018 | 383 | 0.450 |
Why?
| | Drug Users | 1 | 2015 | 42 | 0.450 |
Why?
| | Organ Size | 6 | 2025 | 463 | 0.440 |
Why?
| | Gastrointestinal Microbiome | 2 | 2020 | 771 | 0.430 |
Why?
| | Brain-Derived Neurotrophic Factor | 6 | 2015 | 148 | 0.430 |
Why?
| | Interview, Psychological | 2 | 2011 | 94 | 0.430 |
Why?
| | Anxiety | 3 | 2024 | 1109 | 0.420 |
Why?
| | Cognitive Dysfunction | 1 | 2020 | 461 | 0.420 |
Why?
| | Photic Stimulation | 5 | 2014 | 264 | 0.420 |
Why?
| | Cerebrum | 1 | 2013 | 7 | 0.410 |
Why?
| | Prefrontal Cortex | 3 | 2014 | 328 | 0.410 |
Why?
| | Retinal Dehydrogenase | 1 | 2013 | 29 | 0.410 |
Why?
| | Epigenesis, Genetic | 3 | 2013 | 684 | 0.400 |
Why?
| | Treatment Outcome | 15 | 2017 | 11679 | 0.390 |
Why?
| | Age Factors | 4 | 2026 | 3333 | 0.390 |
Why?
| | Chronic Pain | 1 | 2018 | 290 | 0.390 |
Why?
| | Sex Factors | 9 | 2025 | 2112 | 0.380 |
Why?
| | Biomedical Research | 1 | 2019 | 710 | 0.380 |
Why?
| | alpha-Synuclein | 1 | 2013 | 46 | 0.380 |
Why?
| | Body Weight | 1 | 2017 | 976 | 0.380 |
Why?
| | Receptors, Neurokinin-1 | 1 | 2012 | 8 | 0.380 |
Why?
| | Pirenzepine | 2 | 2003 | 8 | 0.380 |
Why?
| | Genome-Wide Association Study | 3 | 2016 | 1406 | 0.370 |
Why?
| | Models, Psychological | 6 | 2011 | 299 | 0.370 |
Why?
| | Analysis of Variance | 12 | 2012 | 1306 | 0.370 |
Why?
| | Attention | 4 | 2020 | 457 | 0.360 |
Why?
| | Mouth | 2 | 2024 | 88 | 0.350 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2011 | 46 | 0.350 |
Why?
| | Dose-Response Relationship, Drug | 9 | 2015 | 2027 | 0.350 |
Why?
| | Receptor, Muscarinic M2 | 1 | 2011 | 10 | 0.350 |
Why?
| | Cytokines | 3 | 2025 | 2061 | 0.350 |
Why?
| | Personality | 2 | 2006 | 132 | 0.340 |
Why?
| | Secondary Prevention | 2 | 2023 | 254 | 0.340 |
Why?
| | Cytidine Deaminase | 1 | 2011 | 59 | 0.340 |
Why?
| | Pharmacogenetics | 2 | 2010 | 172 | 0.340 |
Why?
| | Protons | 1 | 2011 | 95 | 0.330 |
Why?
| | Surveys and Questionnaires | 19 | 2013 | 6048 | 0.330 |
Why?
| | Extinction, Psychological | 1 | 2012 | 92 | 0.330 |
Why?
| | Limbic System | 2 | 2008 | 55 | 0.320 |
Why?
| | Intelligence | 1 | 2011 | 112 | 0.320 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2011 | 99 | 0.320 |
Why?
| | Gene Deletion | 1 | 2011 | 389 | 0.310 |
Why?
| | Gene Expression | 3 | 2010 | 1490 | 0.310 |
Why?
| | Alleles | 6 | 2011 | 879 | 0.300 |
Why?
| | Choice Behavior | 1 | 2011 | 177 | 0.300 |
Why?
| | Personality Inventory | 5 | 2011 | 134 | 0.300 |
Why?
| | Students | 3 | 2011 | 663 | 0.300 |
Why?
| | Text Messaging | 1 | 2012 | 182 | 0.300 |
Why?
| | Connectome | 3 | 2024 | 95 | 0.290 |
Why?
| | Proteins | 2 | 2013 | 1021 | 0.290 |
Why?
| | Genomics | 2 | 2012 | 834 | 0.290 |
Why?
| | Psychotherapy, Group | 1 | 2009 | 80 | 0.290 |
Why?
| | Diabetes Mellitus | 1 | 2018 | 1098 | 0.290 |
Why?
| | Avoidance Learning | 1 | 2009 | 64 | 0.290 |
Why?
| | Genetic Linkage | 1 | 2009 | 273 | 0.280 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2007 | 6 | 0.270 |
Why?
| | Breath Tests | 5 | 2009 | 79 | 0.270 |
Why?
| | Case-Control Studies | 11 | 2026 | 3604 | 0.270 |
Why?
| | Colorado | 5 | 2025 | 4564 | 0.270 |
Why?
| | Alcohols | 1 | 2007 | 28 | 0.260 |
Why?
| | Methylation | 2 | 2018 | 242 | 0.260 |
Why?
| | Image Processing, Computer-Assisted | 8 | 2016 | 780 | 0.260 |
Why?
| | Counseling | 1 | 2011 | 408 | 0.260 |
Why?
| | Obesity | 2 | 2018 | 3077 | 0.260 |
Why?
| | Depression | 2 | 2024 | 1558 | 0.260 |
Why?
| | Infusions, Intravenous | 4 | 2018 | 423 | 0.260 |
Why?
| | Drug Resistance | 1 | 2007 | 153 | 0.260 |
Why?
| | Acoustic Stimulation | 3 | 2013 | 333 | 0.250 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2024 | 1720 | 0.250 |
Why?
| | Health Education | 1 | 2009 | 358 | 0.240 |
Why?
| | Hydrocortisone | 1 | 2008 | 304 | 0.240 |
Why?
| | Mental Health | 2 | 2025 | 790 | 0.230 |
Why?
| | Lipoxygenase | 1 | 2025 | 15 | 0.230 |
Why?
| | Physical Fitness | 2 | 2020 | 209 | 0.230 |
Why?
| | Biomarkers | 4 | 2025 | 4271 | 0.230 |
Why?
| | Diagnostic Imaging | 1 | 2008 | 338 | 0.230 |
Why?
| | Microbiota | 3 | 2024 | 781 | 0.230 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2025 | 74 | 0.230 |
Why?
| | Genetic Association Studies | 5 | 2015 | 372 | 0.220 |
Why?
| | Homosexuality, Female | 1 | 2005 | 40 | 0.220 |
Why?
| | Program Evaluation | 1 | 2009 | 948 | 0.220 |
Why?
| | Self Concept | 1 | 2007 | 253 | 0.220 |
Why?
| | Helplessness, Learned | 1 | 2005 | 67 | 0.220 |
Why?
| | Body Mass Index | 4 | 2020 | 2438 | 0.220 |
Why?
| | Adolescent Behavior | 3 | 2021 | 501 | 0.220 |
Why?
| | CpG Islands | 2 | 2016 | 165 | 0.210 |
Why?
| | Patient-Centered Care | 1 | 2010 | 544 | 0.210 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2025 | 162 | 0.210 |
Why?
| | Social Perception | 1 | 2005 | 107 | 0.210 |
Why?
| | Genome, Human | 3 | 2012 | 422 | 0.210 |
Why?
| | Homosexuality, Male | 1 | 2005 | 222 | 0.200 |
Why?
| | Tobacco Use | 1 | 2024 | 61 | 0.200 |
Why?
| | Anti-Anxiety Agents | 1 | 2024 | 45 | 0.200 |
Why?
| | Dopamine Uptake Inhibitors | 2 | 2003 | 58 | 0.200 |
Why?
| | Schizophrenia | 2 | 2025 | 446 | 0.200 |
Why?
| | Alcohol Abstinence | 2 | 2014 | 13 | 0.200 |
Why?
| | Aspartic Acid | 3 | 2012 | 88 | 0.200 |
Why?
| | Nervous System Diseases | 1 | 2026 | 284 | 0.190 |
Why?
| | Habituation, Psychophysiologic | 1 | 2003 | 58 | 0.190 |
Why?
| | Chi-Square Distribution | 4 | 2012 | 529 | 0.190 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2022 | 55 | 0.180 |
Why?
| | Cross-Over Studies | 2 | 2023 | 601 | 0.180 |
Why?
| | Sequence Analysis, DNA | 2 | 2020 | 824 | 0.180 |
Why?
| | Phosphocreatine | 2 | 2012 | 44 | 0.180 |
Why?
| | Central Nervous System Stimulants | 2 | 2004 | 185 | 0.180 |
Why?
| | Psychotic Disorders | 1 | 2024 | 186 | 0.180 |
Why?
| | Creatine | 2 | 2012 | 63 | 0.180 |
Why?
| | Blood Pressure | 5 | 2018 | 1769 | 0.180 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2021 | 45 | 0.180 |
Why?
| | Homozygote | 2 | 2012 | 199 | 0.180 |
Why?
| | Individuality | 5 | 2011 | 152 | 0.180 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2024 | 558 | 0.170 |
Why?
| | Psychiatric Status Rating Scales | 4 | 2011 | 541 | 0.170 |
Why?
| | Harm Reduction | 1 | 2021 | 51 | 0.170 |
Why?
| | United States | 7 | 2026 | 15966 | 0.170 |
Why?
| | Frontal Lobe | 2 | 2013 | 160 | 0.160 |
Why?
| | Axons | 2 | 2013 | 201 | 0.160 |
Why?
| | Cerebellar Cortex | 1 | 2021 | 20 | 0.160 |
Why?
| | Inflammation | 2 | 2025 | 2878 | 0.160 |
Why?
| | Hippocampus | 3 | 2021 | 965 | 0.160 |
Why?
| | Glutamic Acid | 2 | 2012 | 251 | 0.160 |
Why?
| | Dextroamphetamine | 1 | 1999 | 4 | 0.160 |
Why?
| | Verbal Learning | 1 | 2020 | 73 | 0.160 |
Why?
| | Promoter Regions, Genetic | 2 | 2018 | 1257 | 0.160 |
Why?
| | Support Vector Machine | 2 | 2018 | 36 | 0.150 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2452 | 0.150 |
Why?
| | DNA Mutational Analysis | 3 | 2012 | 406 | 0.150 |
Why?
| | Dopamine and cAMP-Regulated Phosphoprotein 32 | 2 | 2011 | 9 | 0.150 |
Why?
| | Alcohol Deterrents | 2 | 2018 | 26 | 0.150 |
Why?
| | Drug and Narcotic Control | 1 | 2019 | 24 | 0.150 |
Why?
| | Sexual Behavior | 2 | 2021 | 491 | 0.150 |
Why?
| | Knowledge | 1 | 2019 | 57 | 0.150 |
Why?
| | Sympathomimetics | 1 | 1999 | 19 | 0.150 |
Why?
| | Brain Chemistry | 2 | 2011 | 116 | 0.150 |
Why?
| | Comorbidity | 2 | 2018 | 1658 | 0.150 |
Why?
| | Amphetamine | 1 | 1999 | 38 | 0.150 |
Why?
| | Health Behavior | 3 | 2013 | 785 | 0.150 |
Why?
| | Juvenile Delinquency | 2 | 2013 | 95 | 0.150 |
Why?
| | Risk Reduction Behavior | 1 | 2021 | 226 | 0.150 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 594 | 0.140 |
Why?
| | Aged | 6 | 2026 | 25913 | 0.140 |
Why?
| | Pain | 1 | 2024 | 779 | 0.140 |
Why?
| | Cross-Sectional Studies | 5 | 2017 | 5868 | 0.140 |
Why?
| | Neuropsychological Tests | 6 | 2018 | 1134 | 0.140 |
Why?
| | Environment | 2 | 2010 | 305 | 0.140 |
Why?
| | Underage Drinking | 1 | 2018 | 22 | 0.140 |
Why?
| | Cocaine-Related Disorders | 2 | 2018 | 132 | 0.140 |
Why?
| | Placebo Effect | 1 | 2017 | 25 | 0.130 |
Why?
| | Mass Spectrometry | 1 | 2021 | 750 | 0.130 |
Why?
| | Tobacco Smoking | 1 | 2017 | 26 | 0.130 |
Why?
| | Dysbiosis | 1 | 2019 | 187 | 0.130 |
Why?
| | Speech | 2 | 2012 | 77 | 0.130 |
Why?
| | Benzazepines | 1 | 2017 | 35 | 0.130 |
Why?
| | Southwestern United States | 1 | 2017 | 95 | 0.130 |
Why?
| | Research Design | 3 | 2019 | 1135 | 0.130 |
Why?
| | Information Dissemination | 1 | 2019 | 223 | 0.130 |
Why?
| | Postural Balance | 1 | 2020 | 240 | 0.130 |
Why?
| | Gene Frequency | 3 | 2008 | 481 | 0.130 |
Why?
| | Pilot Projects | 5 | 2019 | 1886 | 0.130 |
Why?
| | Beverages | 1 | 2017 | 69 | 0.120 |
Why?
| | Interleukin-8 | 1 | 2018 | 271 | 0.120 |
Why?
| | Insulin Resistance | 1 | 2025 | 1241 | 0.120 |
Why?
| | Amygdala | 2 | 2021 | 198 | 0.120 |
Why?
| | Food Preferences | 1 | 2017 | 126 | 0.120 |
Why?
| | Interleukin-1beta | 1 | 2018 | 395 | 0.120 |
Why?
| | Reaction Time | 2 | 2011 | 438 | 0.120 |
Why?
| | Behavior | 2 | 2009 | 91 | 0.110 |
Why?
| | Exercise Therapy | 1 | 2020 | 473 | 0.110 |
Why?
| | Proton Magnetic Resonance Spectroscopy | 1 | 2015 | 20 | 0.110 |
Why?
| | Placebos | 3 | 2007 | 192 | 0.110 |
Why?
| | Public Policy | 1 | 2015 | 79 | 0.110 |
Why?
| | Follow-Up Studies | 4 | 2013 | 5408 | 0.110 |
Why?
| | Models, Neurological | 2 | 2015 | 254 | 0.110 |
Why?
| | Radiography | 2 | 2015 | 844 | 0.110 |
Why?
| | Hypnotics and Sedatives | 2 | 2009 | 216 | 0.110 |
Why?
| | Legislation, Drug | 1 | 2015 | 73 | 0.110 |
Why?
| | Animals | 8 | 2019 | 38058 | 0.110 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2015 | 145 | 0.110 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 2 | 2012 | 62 | 0.110 |
Why?
| | Signal Transduction | 3 | 2019 | 5226 | 0.100 |
Why?
| | Energy Intake | 1 | 2017 | 499 | 0.100 |
Why?
| | Drug Interactions | 2 | 2007 | 398 | 0.100 |
Why?
| | Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2013 | 27 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 427 | 0.100 |
Why?
| | Interleukin-6 | 1 | 2018 | 780 | 0.100 |
Why?
| | Nerve Tissue Proteins | 2 | 2010 | 592 | 0.100 |
Why?
| | Nucleus Accumbens | 2 | 2021 | 132 | 0.100 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2013 | 28 | 0.100 |
Why?
| | Basal Ganglia | 1 | 2013 | 57 | 0.100 |
Why?
| | Sample Size | 1 | 2013 | 123 | 0.100 |
Why?
| | Factor Analysis, Statistical | 2 | 2015 | 293 | 0.100 |
Why?
| | Stress Disorders, Traumatic | 1 | 2013 | 24 | 0.100 |
Why?
| | Bacteria | 1 | 2020 | 889 | 0.100 |
Why?
| | Models, Genetic | 2 | 2007 | 536 | 0.100 |
Why?
| | Nerve Fibers, Unmyelinated | 1 | 2012 | 8 | 0.100 |
Why?
| | Norepinephrine | 1 | 2013 | 196 | 0.100 |
Why?
| | Receptors, Serotonin | 1 | 2012 | 35 | 0.090 |
Why?
| | Hypothalamo-Hypophyseal System | 2 | 2008 | 198 | 0.090 |
Why?
| | Adaptation, Psychological | 2 | 2011 | 717 | 0.090 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2017 | 428 | 0.090 |
Why?
| | Body Temperature | 1 | 2013 | 229 | 0.090 |
Why?
| | Auditory Perception | 1 | 2013 | 114 | 0.090 |
Why?
| | Cerebrospinal Fluid | 1 | 2012 | 88 | 0.090 |
Why?
| | Glutamine | 1 | 2012 | 109 | 0.090 |
Why?
| | Reproducibility of Results | 4 | 2023 | 3409 | 0.090 |
Why?
| | Predictive Value of Tests | 2 | 2012 | 2115 | 0.090 |
Why?
| | Lactic Acid | 1 | 2013 | 302 | 0.090 |
Why?
| | Longitudinal Studies | 3 | 2014 | 2947 | 0.090 |
Why?
| | Glycerylphosphorylcholine | 1 | 2011 | 5 | 0.090 |
Why?
| | Life Style | 2 | 2012 | 479 | 0.090 |
Why?
| | Inositol | 1 | 2011 | 24 | 0.090 |
Why?
| | Phosphorylcholine | 1 | 2011 | 19 | 0.090 |
Why?
| | Heterozygote | 1 | 2012 | 315 | 0.090 |
Why?
| | Gene-Environment Interaction | 1 | 2013 | 180 | 0.090 |
Why?
| | Choline | 1 | 2012 | 136 | 0.090 |
Why?
| | Linear Models | 2 | 2016 | 854 | 0.090 |
Why?
| | Visual Perception | 1 | 2013 | 183 | 0.090 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2011 | 47 | 0.090 |
Why?
| | Neuroanatomy | 2 | 2021 | 8 | 0.090 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2011 | 23 | 0.080 |
Why?
| | Association | 1 | 2011 | 12 | 0.080 |
Why?
| | Genetic Markers | 1 | 2012 | 331 | 0.080 |
Why?
| | Carbon Monoxide | 3 | 2007 | 82 | 0.080 |
Why?
| | Risk | 2 | 2011 | 911 | 0.080 |
Why?
| | Prognosis | 2 | 2017 | 4282 | 0.080 |
Why?
| | Motivational Interviewing | 1 | 2012 | 121 | 0.080 |
Why?
| | Washington | 1 | 2011 | 147 | 0.080 |
Why?
| | Administration, Cutaneous | 2 | 2007 | 125 | 0.080 |
Why?
| | Pregnancy Complications | 1 | 1996 | 592 | 0.080 |
Why?
| | Brain Diseases | 1 | 2011 | 152 | 0.080 |
Why?
| | Pregnanolone | 1 | 2010 | 35 | 0.080 |
Why?
| | Euphoria | 1 | 2009 | 2 | 0.080 |
Why?
| | Genetic Testing | 2 | 2015 | 478 | 0.080 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2010 | 192 | 0.080 |
Why?
| | New Mexico | 1 | 2009 | 99 | 0.080 |
Why?
| | Oxygen Consumption | 1 | 2013 | 724 | 0.080 |
Why?
| | Professional-Patient Relations | 1 | 2011 | 154 | 0.070 |
Why?
| | Smoking Prevention | 2 | 2007 | 166 | 0.070 |
Why?
| | Temperance | 1 | 2009 | 20 | 0.070 |
Why?
| | Social Class | 1 | 2011 | 268 | 0.070 |
Why?
| | Drug Design | 1 | 2010 | 173 | 0.070 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2011 | 630 | 0.070 |
Why?
| | Life Change Events | 2 | 2010 | 147 | 0.070 |
Why?
| | Methamphetamine | 2 | 2019 | 70 | 0.070 |
Why?
| | Presynaptic Terminals | 1 | 2009 | 86 | 0.070 |
Why?
| | Probability | 1 | 2009 | 310 | 0.070 |
Why?
| | Brain Concussion | 1 | 2016 | 640 | 0.070 |
Why?
| | Genetics, Behavioral | 1 | 2007 | 17 | 0.070 |
Why?
| | Gambling | 1 | 2007 | 30 | 0.070 |
Why?
| | DNA Primers | 1 | 2008 | 512 | 0.070 |
Why?
| | Time Factors | 4 | 2006 | 7173 | 0.060 |
Why?
| | Disruptive, Impulse Control, and Conduct Disorders | 1 | 2007 | 10 | 0.060 |
Why?
| | Prospective Studies | 3 | 2013 | 7990 | 0.060 |
Why?
| | Risk Factors | 4 | 2013 | 10779 | 0.060 |
Why?
| | Neostriatum | 1 | 2007 | 37 | 0.060 |
Why?
| | Twins, Dizygotic | 1 | 2007 | 109 | 0.060 |
Why?
| | Opioid-Related Disorders | 1 | 2015 | 600 | 0.060 |
Why?
| | Universities | 1 | 2009 | 452 | 0.060 |
Why?
| | Injections, Intravenous | 1 | 2007 | 200 | 0.060 |
Why?
| | Twins, Monozygotic | 1 | 2007 | 134 | 0.060 |
Why?
| | Physical Exertion | 2 | 2023 | 207 | 0.060 |
Why?
| | Siblings | 1 | 2007 | 195 | 0.060 |
Why?
| | Drinking Behavior | 1 | 2006 | 13 | 0.060 |
Why?
| | Electromyography | 2 | 2000 | 415 | 0.060 |
Why?
| | Synaptic Transmission | 1 | 2008 | 290 | 0.060 |
Why?
| | Self Efficacy | 1 | 2009 | 414 | 0.060 |
Why?
| | Libido | 1 | 2005 | 24 | 0.060 |
Why?
| | Sensation | 1 | 2006 | 55 | 0.060 |
Why?
| | Retrospective Studies | 2 | 2015 | 17066 | 0.060 |
Why?
| | Heterosexuality | 1 | 2005 | 45 | 0.060 |
Why?
| | Social Values | 1 | 2005 | 40 | 0.060 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2005 | 30 | 0.060 |
Why?
| | Health Promotion | 1 | 2012 | 774 | 0.060 |
Why?
| | Stereotyping | 1 | 2005 | 47 | 0.060 |
Why?
| | Bulimia | 1 | 2005 | 35 | 0.060 |
Why?
| | Depressive Disorder | 1 | 2008 | 387 | 0.060 |
Why?
| | DNA | 2 | 2010 | 1463 | 0.060 |
Why?
| | Patient Satisfaction | 1 | 2009 | 704 | 0.060 |
Why?
| | Binding Sites | 2 | 2007 | 1329 | 0.060 |
Why?
| | Synapses | 1 | 2009 | 439 | 0.060 |
Why?
| | Internal-External Control | 1 | 2005 | 75 | 0.060 |
Why?
| | Rivers | 1 | 2005 | 67 | 0.050 |
Why?
| | Appetite | 1 | 2005 | 69 | 0.050 |
Why?
| | Rain | 1 | 2005 | 49 | 0.050 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2005 | 74 | 0.050 |
Why?
| | Cohort Studies | 3 | 2017 | 5960 | 0.050 |
Why?
| | Problem Solving | 1 | 2005 | 156 | 0.050 |
Why?
| | Interpersonal Relations | 1 | 2007 | 400 | 0.050 |
Why?
| | Ganglionic Stimulants | 1 | 2003 | 15 | 0.050 |
Why?
| | Pleasure | 1 | 2023 | 18 | 0.050 |
Why?
| | Disasters | 1 | 2005 | 102 | 0.050 |
Why?
| | Cyproheptadine | 1 | 2003 | 3 | 0.050 |
Why?
| | Rest | 1 | 2024 | 124 | 0.050 |
Why?
| | Serotonin Antagonists | 1 | 2003 | 30 | 0.050 |
Why?
| | Patient Education as Topic | 1 | 2009 | 780 | 0.050 |
Why?
| | Pregnancy | 2 | 1996 | 7190 | 0.050 |
Why?
| | Bupropion | 1 | 2003 | 46 | 0.050 |
Why?
| | Multimodal Imaging | 1 | 2024 | 124 | 0.050 |
Why?
| | Neural Pathways | 2 | 2016 | 311 | 0.050 |
Why?
| | Physical Stimulation | 1 | 2003 | 68 | 0.050 |
Why?
| | Anisotropy | 2 | 2013 | 75 | 0.050 |
Why?
| | Membrane Transport Proteins | 1 | 2004 | 154 | 0.050 |
Why?
| | Algorithms | 2 | 2007 | 1837 | 0.050 |
Why?
| | Genetics, Population | 1 | 2004 | 214 | 0.050 |
Why?
| | Child Behavior | 1 | 2004 | 236 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2003 | 312 | 0.050 |
Why?
| | Attitude to Health | 1 | 2005 | 436 | 0.050 |
Why?
| | Emotions | 1 | 2007 | 578 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2005 | 582 | 0.040 |
Why?
| | Atmospheric Pressure | 1 | 2021 | 26 | 0.040 |
Why?
| | Running | 1 | 2023 | 228 | 0.040 |
Why?
| | Cognitive Dissonance | 1 | 2001 | 4 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 85 | 0.040 |
Why?
| | Limit of Detection | 1 | 2021 | 97 | 0.040 |
Why?
| | Quality Control | 1 | 2021 | 163 | 0.040 |
Why?
| | Wechsler Scales | 2 | 2012 | 59 | 0.040 |
Why?
| | Boredom | 1 | 1999 | 2 | 0.040 |
Why?
| | Personality Tests | 1 | 1999 | 12 | 0.040 |
Why?
| | DNA, Ribosomal | 1 | 2020 | 94 | 0.040 |
Why?
| | Psychophysiology | 1 | 1999 | 12 | 0.040 |
Why?
| | Neurons | 1 | 2009 | 1640 | 0.040 |
Why?
| | Receptors, Purinergic | 2 | 1990 | 20 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2007 | 2832 | 0.040 |
Why?
| | Conditioning, Classical | 1 | 2000 | 120 | 0.040 |
Why?
| | Autism Spectrum Disorder | 1 | 2024 | 412 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2020 | 342 | 0.040 |
Why?
| | Quality Indicators, Health Care | 1 | 2021 | 335 | 0.030 |
Why?
| | Thalamus | 2 | 2012 | 125 | 0.030 |
Why?
| | Amphetamine-Related Disorders | 1 | 2018 | 48 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2007 | 2608 | 0.030 |
Why?
| | Blinking | 1 | 1997 | 10 | 0.030 |
Why?
| | Cocaine | 1 | 2019 | 160 | 0.030 |
Why?
| | Hyperkinesis | 1 | 2017 | 16 | 0.030 |
Why?
| | Self Administration | 1 | 2018 | 124 | 0.030 |
Why?
| | Pituitary-Adrenal System | 1 | 1999 | 165 | 0.030 |
Why?
| | Pharmacogenomic Testing | 1 | 2018 | 62 | 0.030 |
Why?
| | Risk Assessment | 1 | 2007 | 3671 | 0.030 |
Why?
| | Association Learning | 1 | 2017 | 71 | 0.030 |
Why?
| | Electroencephalography | 1 | 2000 | 532 | 0.030 |
Why?
| | Central Nervous System Diseases | 1 | 1997 | 74 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 1997 | 213 | 0.030 |
Why?
| | Volition | 1 | 1996 | 34 | 0.030 |
Why?
| | Computer Simulation | 2 | 2015 | 1025 | 0.030 |
Why?
| | Sampling Studies | 1 | 1996 | 99 | 0.030 |
Why?
| | Self-Assessment | 1 | 1996 | 74 | 0.030 |
Why?
| | Pregnancy Trimester, First | 1 | 1996 | 136 | 0.030 |
Why?
| | Maternal Behavior | 1 | 1996 | 84 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 488 | 0.030 |
Why?
| | Conduct Disorder | 1 | 2017 | 160 | 0.030 |
Why?
| | Hemodynamics | 1 | 2000 | 1121 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1997 | 239 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2015 | 174 | 0.030 |
Why?
| | Athletic Performance | 1 | 2015 | 76 | 0.030 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2015 | 151 | 0.030 |
Why?
| | Salivation | 2 | 2007 | 4 | 0.030 |
Why?
| | Event-Related Potentials, P300 | 1 | 2013 | 15 | 0.030 |
Why?
| | Drug-Seeking Behavior | 1 | 2013 | 22 | 0.030 |
Why?
| | Data Interpretation, Statistical | 1 | 2015 | 372 | 0.020 |
Why?
| | Carrier Proteins | 2 | 2004 | 737 | 0.020 |
Why?
| | Placenta | 2 | 1990 | 780 | 0.020 |
Why?
| | Evoked Potentials | 1 | 2013 | 128 | 0.020 |
Why?
| | Chronic Disease | 1 | 1999 | 1813 | 0.020 |
Why?
| | Behavioral Symptoms | 1 | 2012 | 43 | 0.020 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2012 | 58 | 0.020 |
Why?
| | Fornix, Brain | 1 | 2012 | 5 | 0.020 |
Why?
| | Spatial Analysis | 1 | 2012 | 23 | 0.020 |
Why?
| | Research | 1 | 2015 | 431 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1135 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2013 | 521 | 0.020 |
Why?
| | Water | 1 | 2015 | 469 | 0.020 |
Why?
| | Haplotypes | 1 | 2013 | 490 | 0.020 |
Why?
| | Functional Laterality | 1 | 2012 | 241 | 0.020 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2012 | 154 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2012 | 340 | 0.020 |
Why?
| | Luciferases | 1 | 2010 | 152 | 0.020 |
Why?
| | Methods | 1 | 2010 | 69 | 0.020 |
Why?
| | Cerebellum | 1 | 2012 | 223 | 0.020 |
Why?
| | Chromosomes, Human, X | 1 | 2010 | 76 | 0.020 |
Why?
| | Chromosomes | 1 | 2010 | 108 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2010 | 197 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 379 | 0.020 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2009 | 40 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 304 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 983 | 0.020 |
Why?
| | Transfection | 1 | 2010 | 940 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2009 | 232 | 0.020 |
Why?
| | Feedback, Psychological | 1 | 2007 | 23 | 0.020 |
Why?
| | Chewing Gum | 1 | 2007 | 8 | 0.020 |
Why?
| | Beer | 1 | 2007 | 13 | 0.020 |
Why?
| | Tablets | 1 | 2007 | 41 | 0.020 |
Why?
| | Capsules | 1 | 2007 | 43 | 0.020 |
Why?
| | Learning | 1 | 2011 | 452 | 0.020 |
Why?
| | Blood Platelets | 1 | 1990 | 400 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1539 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 8265 | 0.020 |
Why?
| | Child | 2 | 2022 | 22633 | 0.010 |
Why?
| | Demography | 1 | 2007 | 288 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2010 | 1326 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2007 | 284 | 0.010 |
Why?
| | Body Temperature Regulation | 1 | 2007 | 108 | 0.010 |
Why?
| | Radar | 1 | 2005 | 2 | 0.010 |
Why?
| | Patient Acceptance of Health Care | 1 | 2012 | 885 | 0.010 |
Why?
| | Geographic Information Systems | 1 | 2005 | 46 | 0.010 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2007 | 285 | 0.010 |
Why?
| | Psychometrics | 1 | 2009 | 734 | 0.010 |
Why?
| | Geography | 1 | 2005 | 203 | 0.010 |
Why?
| | Cerebrovascular Circulation | 1 | 2007 | 280 | 0.010 |
Why?
| | Texas | 1 | 2005 | 278 | 0.010 |
Why?
| | Administration, Oral | 1 | 2007 | 847 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2009 | 600 | 0.010 |
Why?
| | Patient Compliance | 1 | 2008 | 588 | 0.010 |
Why?
| | Age Distribution | 1 | 2004 | 403 | 0.010 |
Why?
| | Sex Distribution | 1 | 2004 | 386 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2010 | 4154 | 0.010 |
Why?
| | Speech Production Measurement | 1 | 2002 | 12 | 0.010 |
Why?
| | Parent-Child Relations | 1 | 2004 | 270 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 496 | 0.010 |
Why?
| | Adenosine-5'-(N-ethylcarboxamide) | 2 | 1990 | 9 | 0.010 |
Why?
| | Societies, Medical | 1 | 2004 | 887 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2010 | 4557 | 0.010 |
Why?
| | Feeding Behavior | 1 | 2005 | 684 | 0.010 |
Why?
| | Databases, Factual | 1 | 2005 | 1486 | 0.010 |
Why?
| | Adenosine | 2 | 1990 | 255 | 0.010 |
Why?
| | Prevalence | 1 | 2004 | 2834 | 0.010 |
Why?
| | Immune System | 1 | 1997 | 179 | 0.010 |
Why?
| | Cell Membrane | 2 | 1990 | 706 | 0.010 |
Why?
| | Radioligand Assay | 1 | 1990 | 37 | 0.000 |
Why?
| | Tritium | 1 | 1990 | 68 | 0.000 |
Why?
| | 2-Chloroadenosine | 1 | 1989 | 3 | 0.000 |
Why?
| | Guanylyl Imidodiphosphate | 1 | 1989 | 2 | 0.000 |
Why?
| | Guanine Nucleotides | 1 | 1989 | 12 | 0.000 |
Why?
| | Vasodilator Agents | 1 | 1990 | 331 | 0.000 |
Why?
| | Kinetics | 1 | 1989 | 1627 | 0.000 |
Why?
|
|
Hutchison's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|